- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Autosomal dominant polycystic kidney disease (ADPKD)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Tolvaptan – November 2019
Tolvaptan: Tablets 15 mg, Tablets 30 mg, Pack containing 28 tablets 15 mg and 28 tablets 45 mg, Pack containing 28 tablets 30 mg and 28 tablets 60 mg, Pack containing 28 tablets 30 mg and 28 tablets 90 mg; Jinarc®
Last updated
6 March 2020